Form 4: Royalty Pharma EVP Christopher Hite Acquires 300,000 Class A Ordinary Shares Through Partnership Interest Exchange

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, acquired 300,000 Class A Ordinary Shares through an exchange of limited partnership interests.

Summary

• Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, filed a Form 4 detailing changes in beneficial ownership.
• On May 13, 2024, Hite acquired 300,000 Class A Ordinary Shares.
• These shares were acquired through the exchange of limited partnership interests in RPI US Partners 2019, LP (RPI US LP).
• Each RPI US LP Interest is exchangeable for ten Class B Interests in Royalty Pharma Holdings Limited (Holdings), which in turn are exchangeable for one Class A Ordinary Share of Royalty Pharma plc.
• The exchange was made pursuant to the Exchange Agreement dated June 16, 2020.
• No additional value was paid by Hite in connection with the exchange.
• Following the transaction, Hite beneficially owns 370,000 Class A Ordinary Shares indirectly through SCH Investment Partners LLC.
• Hite also holds limited partnership interests in RPI US Partners 2019, LP, which are convertible into approximately 300,000 Class A Ordinary Shares.
• Hite has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into approximately 928,800 Class A Ordinary Shares before February 2025, subject to certain waivable circumstances.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a transaction. The acquisition of shares by an executive is generally viewed as a positive sign, but the document itself is simply a factual disclosure.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but it does mention an agreement by the reporting person to retain shares until February 2025.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in Christopher Hite's ownership of Royalty Pharma shares.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a high-ranking executive.

Key Dates